Hormone Therapy-Chemo Combo Reduces Risk of Tumor Return in Highly Recurrent Breast Cancer, Phase 3 Trial Shows

Hormone Therapy-Chemo Combo Reduces Risk of Tumor Return in Highly Recurrent Breast Cancer, Phase 3 Trial Shows
Using chemotherapy in combination with hormone therapy in women with highly recurring forms of breast cancer reduces the likelihood of disease returning elsewhere in the body over nine years compared with hormone therapy alone, a Phase 3 trial shows. The research, “Clinical Outcomes by Chemotherapy Regimen in Patients with RS 26-100 in TAILORx,” was presented at the recent European Society for Medical Oncology (ESMO) 2019 Congress, in Barcelona, Spain, and also published in JAMA Oncology. TAILORx (NCT00310180) is a Phase 3 study sponsored by the National Cancer Institute (NCI) and led by the ECOG-ACRIN Cancer Research Group. It was designed to determine the best course of treatment for women with highly recurring forms of breast cancer, as defined by the Oncotype DX Breast Recurrence Score test. With more than 1,200 trial sites from six countries, TAILORx is the largest breast cancer treatment
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.